Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that its ...

New lecanemab findings highlight the safety and potential benefits of subcutaneous administration for initiation dosing, the ...

SEYMOUR— To learn more about one of the most bizarre episodes in American history, come to a free presentation on the Salem Witch Trials at 7 p.m. Tuesday, Oct. 28 in the Community Room of the ...

Orbus Therapeutics, Inc., a private pharmaceutical company, today announced it will present updated results from the Phase 3 STELLAR trial investigating eflornithine at the Society for Neuro-Oncology ...

Whether your family is affected by Alzheimer's or you simply want to learn more about the disease, this conference in Boca ...

NEXICART-2 (NCT06097832) is an ongoing multi-site U.S. Phase 1/2 clinical trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory AL Amyloidosis, with a registrational design. Interim ...

NEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Nov. 19, 2025 (GLOBE NEWSWIRE) -- DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and ...

INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces two presentations at the upcoming 18th Clinical Trials on Alzheimer’s Disease conference (CTAD), ...

First presentation of U.S. IDE clinical data shows statistically significant improvements in pain and function at 24 months ...

BioLife Solutions ( ($BLFS) ) has issued an update. On November 17, 2025, BioLife Solutions released an investor presentation highlighting its ...

Black and Hispanic individuals with obesity appear underrepresented in GLP-1 weight loss trials, compared with the overall ...

The latest update is out from Purple Biotech ( (PPBT) ).